JP2015514743A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514743A5 JP2015514743A5 JP2015506317A JP2015506317A JP2015514743A5 JP 2015514743 A5 JP2015514743 A5 JP 2015514743A5 JP 2015506317 A JP2015506317 A JP 2015506317A JP 2015506317 A JP2015506317 A JP 2015506317A JP 2015514743 A5 JP2015514743 A5 JP 2015514743A5
- Authority
- JP
- Japan
- Prior art keywords
- buprenorphine
- pharmaceutical composition
- opioid
- formulated
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 28
- 229960001736 buprenorphine Drugs 0.000 claims 28
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 230000002411 adverse Effects 0.000 claims 8
- 230000003285 pharmacodynamic effect Effects 0.000 claims 8
- 238000013270 controlled release Methods 0.000 claims 6
- BQNSLJQRJAJITR-UHFFFAOYSA-N 1,1,2-trichloro-1,2-difluoroethane Chemical compound FC(Cl)C(F)(Cl)Cl BQNSLJQRJAJITR-UHFFFAOYSA-N 0.000 claims 5
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 5
- 229960003617 oxycodone hydrochloride Drugs 0.000 claims 5
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 4
- 239000008184 oral solid dosage form Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- 230000036592 analgesia Effects 0.000 claims 3
- 230000036506 anxiety Effects 0.000 claims 3
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims 3
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims 3
- 229960000240 hydrocodone Drugs 0.000 claims 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 3
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims 3
- GTPHQORJKFJIRB-JTQLPTLWSA-N (2s)-2-amino-n-[(2r)-1-[[(2s)-1-[[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-fluorophenyl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-3-(4-hydroxyphenyl)propanamide Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)N[C@@H](CC=1C=CC(F)=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=C(O)C=C1 GTPHQORJKFJIRB-JTQLPTLWSA-N 0.000 claims 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 2
- 206010011224 Cough Diseases 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- 208000014540 Functional gastrointestinal disease Diseases 0.000 claims 2
- 208000004454 Hyperalgesia Diseases 0.000 claims 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 2
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims 2
- 230000000202 analgesic effect Effects 0.000 claims 2
- 201000007637 bowel dysfunction Diseases 0.000 claims 2
- 229960004126 codeine Drugs 0.000 claims 2
- 229960002428 fentanyl Drugs 0.000 claims 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 2
- 229950001535 frakefamide Drugs 0.000 claims 2
- 108010028490 frakefamide Proteins 0.000 claims 2
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims 2
- 229960001410 hydromorphone Drugs 0.000 claims 2
- 229960005181 morphine Drugs 0.000 claims 2
- 229960002085 oxycodone Drugs 0.000 claims 2
- 229960005118 oxymorphone Drugs 0.000 claims 2
- 229960004380 tramadol Drugs 0.000 claims 2
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims 2
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 claims 1
- DYUTXEVRMPFGTH-UHFFFAOYSA-N 4-(2,5-dimethylphenyl)-5-methyl-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C(=CC=C(C)C=2)C)=C1C DYUTXEVRMPFGTH-UHFFFAOYSA-N 0.000 claims 1
- 206010000060 Abdominal distension Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000035154 Hyperesthesia Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 206010027646 Miosis Diseases 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- BCGJBQBWUGVESK-KCTCKCTRSA-N Oxymorphone hydrochloride Chemical compound Cl.O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BCGJBQBWUGVESK-KCTCKCTRSA-N 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims 1
- 206010038678 Respiratory depression Diseases 0.000 claims 1
- 206010039897 Sedation Diseases 0.000 claims 1
- 208000032140 Sleepiness Diseases 0.000 claims 1
- 206010041349 Somnolence Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 206010046555 Urinary retention Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 230000003187 abdominal effect Effects 0.000 claims 1
- 206010053552 allodynia Diseases 0.000 claims 1
- 206010003549 asthenia Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 208000024330 bloating Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 230000030136 gastric emptying Effects 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 229960002738 hydromorphone hydrochloride Drugs 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 claims 1
- 229960001571 loperamide Drugs 0.000 claims 1
- 230000003547 miosis Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 229960005374 oxymorphone hydrochloride Drugs 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 230000036280 sedation Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 210000004243 sweat Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000035922 thirst Effects 0.000 claims 1
- 229960003107 tramadol hydrochloride Drugs 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261625361P | 2012-04-17 | 2012-04-17 | |
| US61/625,361 | 2012-04-17 | ||
| US201261673613P | 2012-07-19 | 2012-07-19 | |
| US61/673,613 | 2012-07-19 | ||
| US201261682651P | 2012-08-13 | 2012-08-13 | |
| US61/682,651 | 2012-08-13 | ||
| US201261736299P | 2012-12-12 | 2012-12-12 | |
| US61/736,299 | 2012-12-12 | ||
| US201361791338P | 2013-03-15 | 2013-03-15 | |
| US61/791,338 | 2013-03-15 | ||
| PCT/IB2013/000746 WO2013156850A1 (en) | 2012-04-17 | 2013-04-17 | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018005508A Division JP2018080197A (ja) | 2012-04-17 | 2018-01-17 | オピオイド誘発性有害薬力学的応答を治療するためのシステムおよび方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015514743A JP2015514743A (ja) | 2015-05-21 |
| JP2015514743A5 true JP2015514743A5 (enExample) | 2016-05-26 |
| JP6279547B2 JP6279547B2 (ja) | 2018-02-14 |
Family
ID=48428522
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015506317A Active JP6279547B2 (ja) | 2012-04-17 | 2013-04-17 | オピオイド誘発性有害薬力学的応答を治療するためのシステムおよび方法 |
| JP2018005508A Pending JP2018080197A (ja) | 2012-04-17 | 2018-01-17 | オピオイド誘発性有害薬力学的応答を治療するためのシステムおよび方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018005508A Pending JP2018080197A (ja) | 2012-04-17 | 2018-01-17 | オピオイド誘発性有害薬力学的応答を治療するためのシステムおよび方法 |
Country Status (28)
| Country | Link |
|---|---|
| US (14) | US8946253B2 (enExample) |
| EP (2) | EP3485880B1 (enExample) |
| JP (2) | JP6279547B2 (enExample) |
| KR (2) | KR102196741B1 (enExample) |
| CN (2) | CN110101702A (enExample) |
| AR (1) | AR092820A1 (enExample) |
| AU (3) | AU2013250883B2 (enExample) |
| CA (2) | CA2868413C (enExample) |
| CH (1) | CH708257B1 (enExample) |
| CL (3) | CL2014002790A1 (enExample) |
| CO (1) | CO7141431A2 (enExample) |
| DE (1) | DE112013002074T5 (enExample) |
| EA (1) | EA201491875A1 (enExample) |
| EC (1) | ECSP14027393A (enExample) |
| ES (2) | ES2569743R1 (enExample) |
| GB (1) | GB2517328A (enExample) |
| GT (1) | GT201400223A (enExample) |
| HK (2) | HK1206978A1 (enExample) |
| IL (1) | IL235082B (enExample) |
| IN (1) | IN2014DN09238A (enExample) |
| MX (1) | MX2014011855A (enExample) |
| NZ (1) | NZ631539A (enExample) |
| PE (1) | PE20150020A1 (enExample) |
| PH (1) | PH12014502322A1 (enExample) |
| SG (2) | SG10201803195PA (enExample) |
| TW (3) | TW201811332A (enExample) |
| WO (1) | WO2013156850A1 (enExample) |
| ZA (1) | ZA201408336B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8846765B2 (en) | 2010-06-15 | 2014-09-30 | Gruenenthal Gmbh | Pharmaceutical combination |
| HK1206978A1 (en) * | 2012-04-17 | 2016-01-22 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
| TW201613590A (en) * | 2014-09-12 | 2016-04-16 | Purdue Pharma Lp | Systems and methods for attenuating opioid-induced euphoria |
| US9849124B2 (en) | 2014-10-17 | 2017-12-26 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
| CA3104099A1 (en) | 2015-03-10 | 2016-09-15 | Rhodes Technologies | Acetate salt of buprenorphine and methods for preparing buprenorphine |
| GB201600918D0 (en) * | 2016-01-18 | 2016-03-02 | Buzzz Pharmaceuticals Ltd | Transdermal patch |
| WO2018125716A1 (en) | 2017-01-02 | 2018-07-05 | Purdue Pharma L.P. | Morphinan derivatives and use thereof |
| CA3068036A1 (en) * | 2017-06-30 | 2019-01-03 | Purdue Pharma L.P. | Use to buprenorphine in combination with an opioid to treat pain |
| AU2018351502B2 (en) * | 2017-10-20 | 2024-09-05 | Purdue Pharma L.P. | Pharmaceutical dosage forms |
| EP3863712A4 (en) * | 2018-10-11 | 2022-07-20 | Indivior UK Limited | Buprenorphine to treat respiratory depression |
Family Cites Families (127)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| GB1405088A (en) | 1971-06-03 | 1975-09-03 | Mundipharma Ag | Slow release formulation |
| US3965256A (en) | 1972-05-16 | 1976-06-22 | Synergistics | Slow release pharmaceutical compositions |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4063064A (en) | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
| US4200098A (en) | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
| US4285987A (en) | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
| US4466968A (en) * | 1980-11-24 | 1984-08-21 | Dermall, Ltd. | Method for prophylaxis or treatment of emesis and nausea |
| US4416886A (en) * | 1981-07-29 | 1983-11-22 | Dermall Limited | Method of treating pruritis and composition therefor |
| US4987136A (en) | 1982-03-16 | 1991-01-22 | The Rockefeller University | Method for controlling gastrointestinal dysmotility |
| US4443428A (en) | 1982-06-21 | 1984-04-17 | Euroceltique, S.A. | Extended action controlled release compositions |
| US4588580B2 (en) | 1984-07-23 | 1999-02-16 | Alaz Corp | Transdermal administration of fentanyl and device therefor |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| ES2058111T3 (es) | 1986-06-10 | 1994-11-01 | Euro Celtique Sa | Composicion de liberacion controlada de dihidrocodeina. |
| US4769372A (en) | 1986-06-18 | 1988-09-06 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
| US4785000A (en) | 1986-06-18 | 1988-11-15 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
| US4970075A (en) | 1986-07-18 | 1990-11-13 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
| US4861598A (en) | 1986-07-18 | 1989-08-29 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
| GB8626098D0 (en) | 1986-10-31 | 1986-12-03 | Euro Celtique Sa | Controlled release hydromorphone composition |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| US5656295A (en) | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
| US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| US5286493A (en) | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5681585A (en) | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
| US5478577A (en) | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
| US5273760A (en) | 1991-12-24 | 1993-12-28 | Euroceltigue, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
| US5968551A (en) | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
| US5472712A (en) | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| US5985880A (en) * | 1996-06-05 | 1999-11-16 | Delta Pharmaceuticals | Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds |
| US5324351A (en) | 1992-08-13 | 1994-06-28 | Euroceltique | Aqueous dispersions of zein and preparation thereof |
| US5512578A (en) * | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IL110014A (en) | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
| US6210714B1 (en) | 1993-11-23 | 2001-04-03 | Euro-Celtique S.A. | Immediate release tablet cores of acetaminophen having sustained-release coating |
| US5500227A (en) | 1993-11-23 | 1996-03-19 | Euro-Celtique, S.A. | Immediate release tablet cores of insoluble drugs having sustained-release coating |
| US5891471A (en) | 1993-11-23 | 1999-04-06 | Euro-Celtique, S.A. | Pharmaceutical multiparticulates |
| KR100354702B1 (ko) | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | 약학조성물의제조방법및서방형조성물 |
| US5843480A (en) | 1994-03-14 | 1998-12-01 | Euro-Celtique, S.A. | Controlled release diamorphine formulation |
| US5411745A (en) | 1994-05-25 | 1995-05-02 | Euro-Celtique, S.A. | Powder-layered morphine sulfate formulations |
| US5914131A (en) | 1994-07-07 | 1999-06-22 | Alza Corporation | Hydromorphone therapy |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| US6881208B1 (en) | 1995-06-05 | 2005-04-19 | Joseph B. Phipps | Method and device for transdermal electrotransport delivery of fentanyl and sufentanil |
| FR2738741B1 (fr) * | 1995-09-19 | 1997-12-05 | Oreal | Composition pour la teinture des fibres keratiniques, contenant un antagoniste de substance p |
| WO1997045091A2 (en) | 1996-05-31 | 1997-12-04 | Euro-Celtique, S.A. | Sustained release oxycodone formulations with no fed/fast effect |
| US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
| ATE220015T1 (de) | 1997-09-26 | 2002-07-15 | Magna Interior Sys Inc | Befestigungsvorrichtung zum verbinden von zwei innenpaneelen |
| US6559158B1 (en) | 1997-11-03 | 2003-05-06 | Ur Labs, Inc. | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
| ES2412409T3 (es) | 1997-12-22 | 2013-07-11 | Euro-Celtique S.A. | Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo |
| US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
| CN1204890C (zh) | 1997-12-22 | 2005-06-08 | 欧罗赛铁克股份有限公司 | 防止阿片样物质滥用的方法 |
| ATE467620T1 (de) | 1999-03-26 | 2010-05-15 | Euro Celtique Sa | Arylsubstituierte pyrazole, imidazole, oxazole, thiazole und pyrrole, sowie deren verwendung |
| IL148343A0 (en) | 1999-08-27 | 2002-09-12 | Southern Res Inst | Injectable buprenorphine microparticle compositions and their use |
| WO2001032148A1 (en) | 1999-10-29 | 2001-05-10 | Euro-Celtique, S.A. | Controlled release hydrocodone formulations |
| SI1299104T1 (sl) | 2000-02-08 | 2009-10-31 | Euro Celtique Sa | Oralne formulacije opioidnih agonistov, varne pred zlorabo |
| US6716449B2 (en) | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
| CN101317825A (zh) | 2000-10-30 | 2008-12-10 | 欧罗赛铁克股份有限公司 | 控释氢可酮制剂 |
| DE60236496D1 (de) * | 2001-03-23 | 2010-07-08 | Einstein Coll Med | Verfahren zur erhöhung der analgetischen wirkung und zur verringerung der unerwünschten exitatorischen wirkungen von bimodalisch wirksamen opioidagonisten durch die hemmung von gm1-gangliosid |
| US20030065002A1 (en) | 2001-05-11 | 2003-04-03 | Endo Pharmaceuticals, Inc. | Abuse-resistant controlled-release opioid dosage form |
| US7144587B2 (en) | 2001-08-06 | 2006-12-05 | Euro-Celtique S.A. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent |
| US7842307B2 (en) | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
| US7157103B2 (en) | 2001-08-06 | 2007-01-02 | Euro-Celtique S.A. | Pharmaceutical formulation containing irritant |
| US7332182B2 (en) | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
| US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
| US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
| US7141250B2 (en) | 2001-08-06 | 2006-11-28 | Euro-Celtique S.A. | Pharmaceutical formulation containing bittering agent |
| DE10147501A1 (de) | 2001-09-26 | 2003-04-10 | Wella Ag | Perlglänzende Haarkur |
| US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| ES2320748T5 (es) | 2002-04-05 | 2017-02-20 | Euro-Celtique S.A. | Matriz para la liberación sostenida, invariable e independiente de compuestos activos |
| AU2003240493B2 (en) | 2002-05-31 | 2008-06-12 | L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. | Implantable polymeric device for sustained release of buprenorphine |
| US7413748B2 (en) * | 2002-12-13 | 2008-08-19 | Purdue Pharma L.P. | Transdermal buprenorphine to treat pain in sickle cell crisis |
| JP2006527236A (ja) * | 2003-06-10 | 2006-11-30 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | オピオイド鎮痛薬と組合せた置換１，４−ジ−ピペリジン−４−イル−ピペラジン誘導体ならびに疼痛およびオピオイドに基づく処置に伴う副作用の処置のためのそれらの使用 |
| UA81056C2 (en) * | 2003-07-25 | 2007-11-26 | Euro Celtic S A | Method for treatment of dependence withdrawal in pregnant women by transdermal administration of buprenorphine |
| US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
| TW201509943A (zh) | 2004-03-30 | 2015-03-16 | Euro Celtique Sa | 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝 |
| SG173326A1 (en) | 2004-06-04 | 2011-08-29 | Camurus Ab | Liquid depot formulations |
| DE102005007859A1 (de) | 2005-02-21 | 2006-08-24 | Lts Lohmann Therapie-Systeme Ag | Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen |
| EP1695700A1 (en) | 2005-02-28 | 2006-08-30 | Euro-Celtique S.A. | Dosage form containing oxycodone and naloxone |
| US20060281775A1 (en) | 2005-06-14 | 2006-12-14 | Applied Pharmacy Services, Inc. | Two-component pharmaceutical composition for the treatment of pain |
| WO2007005716A2 (en) | 2005-06-30 | 2007-01-11 | Cinergen, Llc | Methods of treatment and compositions for use thereof |
| WO2007013975A2 (en) | 2005-07-20 | 2007-02-01 | Pharmorx Inc. | Composition containing an opioid agonist and a partial opioid agonist, preferably buprenorphine , for controlling abuse of medications |
| US9265732B2 (en) | 2006-03-06 | 2016-02-23 | Pozen Inc. | Dosage forms for administering combinations of drugs |
| EP2040698A4 (en) * | 2006-07-14 | 2011-08-10 | Shionogi & Co | OXIM CONNECTIONS AND ITS USE |
| RS54764B1 (sr) | 2006-07-21 | 2016-10-31 | Biodelivery Sciences Int Inc | Sredstvo za transmukozalnu isporuku sa povećanim nakupljanjem |
| WO2008036980A1 (en) | 2006-09-22 | 2008-03-27 | Alltranz Inc. | Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof |
| SI2124556T1 (sl) | 2006-10-09 | 2015-01-30 | Charleston Laboratories, Inc. | Farmacevtske sestave |
| US8093261B2 (en) | 2006-10-24 | 2012-01-10 | The Johns Hopkins University | Rapid release mini-tablets provide analgesia in laboratory animals |
| CN101534827A (zh) | 2006-11-07 | 2009-09-16 | 尼克塔治疗亚拉巴马公司 | 阿片样物质激动剂和阿片样物质拮抗剂的剂型和联合给药 |
| US20080199407A1 (en) | 2007-02-15 | 2008-08-21 | Slater Kenneth C | Drug Detoxification Protocol Using Microdosing |
| GB2447013A (en) | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Analgesic composition containing buprenorphone and nalmefene |
| DE102007021549A1 (de) * | 2007-05-08 | 2008-11-13 | Novosis Ag | Transdermales therapeutisches System enthaltend mindestens zwei Opioide |
| EP2240022B1 (en) | 2008-01-09 | 2016-12-28 | Charleston Laboratories, Inc. | Bilayered tablets comprising oxycodone and promethazine |
| EP2262367A4 (en) | 2008-03-08 | 2011-04-20 | Theraquest Biosciences Inc | PHARMACEUTICAL ORAL COMPOSITIONS OF BUPRENORPHINE AND METHOD FOR THEIR USE |
| AU2009223061B2 (en) | 2008-03-11 | 2014-10-09 | Depomed Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
| US20090246265A1 (en) | 2008-03-26 | 2009-10-01 | Alltranz Inc. | Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists |
| TWI473614B (zh) | 2008-05-29 | 2015-02-21 | Kyowa Hakko Kirin Co Ltd | Anti-analgesic inhibitors |
| US8163731B2 (en) | 2008-08-20 | 2012-04-24 | Rhodes Technologies | Method and dosage regimens for eliminating a chemical substance in blood |
| US20100227876A1 (en) | 2009-03-06 | 2010-09-09 | Rechfensen Llp | Methods of Reducing Side Effects of Analgesics |
| WO2010141505A1 (en) | 2009-06-01 | 2010-12-09 | Protect Pharmaceutical Corporation | Abuse-resistant delivery systems |
| US20110046173A1 (en) | 2009-08-24 | 2011-02-24 | Warren Charles Stern | Combination analgesic opioid pain therapy |
| US8461171B2 (en) | 2010-02-09 | 2013-06-11 | QRxPharma Ltd. | Hybrid opioid compounds and compositions |
| WO2011109743A2 (en) * | 2010-03-04 | 2011-09-09 | Rand Jerry N | Synergistic effects of combinations of buprenorphine and opioids for the treatment of pain |
| ES2592277T3 (es) | 2010-04-02 | 2016-11-29 | Buzzz Pharmaceuticals Limited | Formulaciones transdérmicas disuasorias del abuso de agonistas y agonistas-antagonistas opiáceos |
| GB2513267B (en) | 2010-06-08 | 2015-03-18 | Rb Pharmaceuticals Ltd | Injectable flowable composition comprising buprenorphine |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| US8975270B2 (en) | 2010-06-08 | 2015-03-10 | Rb Pharmaceuticals Limited | Injectable flowable composition comprising buprenorphine |
| DE102010048883A1 (de) | 2010-10-19 | 2012-04-19 | Lars Holger Hermann | Verwendung von Buprenorphin zum Abususschutz von Opiat-Vollagonisten sowie entsprechende pharmazeutische Zusammensetzungen |
| KR101572336B1 (ko) | 2010-12-22 | 2015-11-26 | 퍼듀 퍼머 엘피 | 케이싱된 탬퍼 저항성 제어 방출 투여 형태 |
| PH12013501345A1 (en) | 2010-12-23 | 2022-10-24 | Purdue Pharma Lp | Tamper resistant solid oral dosage forms |
| CA2831218C (en) | 2011-03-25 | 2017-01-17 | Purdue Pharma L.P. | Controlled release pharmaceutical dosage forms |
| AU2012262061A1 (en) | 2011-05-31 | 2013-05-09 | QRxPharma Ltd. | Compositions for sequential administration of opioid receptor agonists |
| PL2726064T3 (pl) | 2011-06-30 | 2017-06-30 | Develco Pharma Schweiz Ag | Doustna postać użytkowa o kontrolowanym uwalnianiu zawierająca oksykodon |
| US9211293B2 (en) | 2011-12-15 | 2015-12-15 | Alkermes Pharma Ireland Limited | Opioid agonist antagonist combinations |
| US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
| US9566241B2 (en) | 2012-02-21 | 2017-02-14 | Auburn University | Buprenorphine nanoparticle composition and methods thereof |
| HK1206978A1 (en) | 2012-04-17 | 2016-01-22 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
| RU2012122945A (ru) | 2012-06-04 | 2013-12-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения и социального развития Российской Федерации | Аналгетическое средство |
| US9636308B2 (en) | 2013-03-15 | 2017-05-02 | Oakwood Laboratories LLC | High drug load buprenorphine microspheres and method of producing same |
-
2013
- 2013-04-17 HK HK15107574.2A patent/HK1206978A1/xx unknown
- 2013-04-17 AR ARP130101265A patent/AR092820A1/es unknown
- 2013-04-17 SG SG10201803195PA patent/SG10201803195PA/en unknown
- 2013-04-17 WO PCT/IB2013/000746 patent/WO2013156850A1/en not_active Ceased
- 2013-04-17 US US13/864,791 patent/US8946253B2/en active Active
- 2013-04-17 CA CA2868413A patent/CA2868413C/en active Active
- 2013-04-17 ES ES201490114A patent/ES2569743R1/es active Pending
- 2013-04-17 GB GB1420293.1A patent/GB2517328A/en not_active Withdrawn
- 2013-04-17 TW TW106121617A patent/TW201811332A/zh unknown
- 2013-04-17 EA EA201491875A patent/EA201491875A1/ru unknown
- 2013-04-17 ES ES13722059T patent/ES2716570T3/es active Active
- 2013-04-17 CN CN201910192656.0A patent/CN110101702A/zh active Pending
- 2013-04-17 KR KR1020207004929A patent/KR102196741B1/ko active Active
- 2013-04-17 DE DE112013002074.2T patent/DE112013002074T5/de not_active Withdrawn
- 2013-04-17 AU AU2013250883A patent/AU2013250883B2/en active Active
- 2013-04-17 TW TW102113636A patent/TWI522101B/zh not_active IP Right Cessation
- 2013-04-17 IN IN9238DEN2014 patent/IN2014DN09238A/en unknown
- 2013-04-17 NZ NZ631539A patent/NZ631539A/en not_active IP Right Cessation
- 2013-04-17 EP EP18213538.4A patent/EP3485880B1/en active Active
- 2013-04-17 SG SG11201406025UA patent/SG11201406025UA/en unknown
- 2013-04-17 CA CA3120681A patent/CA3120681C/en active Active
- 2013-04-17 PE PE2014001670A patent/PE20150020A1/es not_active Application Discontinuation
- 2013-04-17 JP JP2015506317A patent/JP6279547B2/ja active Active
- 2013-04-17 MX MX2014011855A patent/MX2014011855A/es unknown
- 2013-04-17 CN CN201380020151.7A patent/CN104302280A/zh active Pending
- 2013-04-17 HK HK15108344.9A patent/HK1207586A1/xx unknown
- 2013-04-17 EP EP13722059.6A patent/EP2844236B1/en active Active
- 2013-04-17 CH CH01619/14A patent/CH708257B1/de active IP Right Maintenance
- 2013-04-17 KR KR1020147031757A patent/KR102082529B1/ko active Active
- 2013-04-17 TW TW104140545A patent/TW201625251A/zh unknown
-
2014
- 2014-10-07 IL IL235082A patent/IL235082B/en active IP Right Grant
- 2014-10-16 CL CL2014002790A patent/CL2014002790A1/es unknown
- 2014-10-17 PH PH12014502322A patent/PH12014502322A1/en unknown
- 2014-10-17 GT GT201400223A patent/GT201400223A/es unknown
- 2014-11-13 ZA ZA2014/08336A patent/ZA201408336B/en unknown
- 2014-11-13 CO CO14251110A patent/CO7141431A2/es unknown
- 2014-11-17 EC ECIEPI201427393A patent/ECSP14027393A/es unknown
- 2014-12-05 US US14/562,170 patent/US9931337B2/en active Active
-
2015
- 2015-01-14 CL CL2015000110A patent/CL2015000110A1/es unknown
- 2015-02-03 US US14/612,941 patent/US9872856B2/en active Active
- 2015-02-26 US US14/632,152 patent/US9662326B2/en active Active
- 2015-03-26 US US14/669,475 patent/US9855262B2/en active Active
- 2015-03-26 US US14/669,481 patent/US9884059B2/en active Active
- 2015-03-26 US US14/669,496 patent/US9867817B2/en active Active
- 2015-03-26 US US14/669,486 patent/US20150196553A1/en not_active Abandoned
- 2015-03-26 US US14/669,499 patent/US20150196549A1/en not_active Abandoned
- 2015-03-26 US US14/669,490 patent/US20150196548A1/en not_active Abandoned
- 2015-09-24 CL CL2015002847A patent/CL2015002847A1/es unknown
-
2016
- 2016-10-12 AU AU2016244249A patent/AU2016244249B2/en active Active
-
2017
- 2017-12-18 US US15/845,642 patent/US10398690B2/en active Active
-
2018
- 2018-01-17 JP JP2018005508A patent/JP2018080197A/ja active Pending
- 2018-11-08 AU AU2018260882A patent/AU2018260882A1/en not_active Abandoned
-
2019
- 2019-07-31 US US16/528,078 patent/US20200155542A1/en not_active Abandoned
-
2021
- 2021-03-16 US US17/202,518 patent/US20210196706A1/en not_active Abandoned
-
2024
- 2024-02-08 US US18/436,555 patent/US20240350479A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015514743A5 (enExample) | ||
| CA2782529C (en) | Morphinan derivatives for the treatment of drug overdose | |
| JP2011519930A5 (enExample) | ||
| ES2278647T3 (es) | Nuevos procedimientos y composiciones que comprenden opioides y antagonistas de opioides. | |
| JP6279547B2 (ja) | オピオイド誘発性有害薬力学的応答を治療するためのシステムおよび方法 | |
| WO2007005716A2 (en) | Methods of treatment and compositions for use thereof | |
| ME01262B (me) | OBLIK ZA DOZIRANJE KOJI SADRŽI OKSIKODON l NALOKSON | |
| JP2011137020A5 (enExample) | ||
| WO2020055725A4 (en) | Dopamine d3 receptor selective antagonists/partial agonists and uses thereof | |
| ES2253662T3 (es) | Procedimiento de tratamiento de un paciente que requiere analgesia. | |
| EA200870182A1 (ru) | Применение комбинации морфина и по меньшей мере одного антагониста опиатов для лечения зависимости от опиатов для предотвращения непероральной опиатомании у наркоманов | |
| JP2017526719A5 (enExample) | ||
| JP2010540648A5 (enExample) | ||
| JP2014505113A (ja) | 末梢作用性μオピオイドアンタゴニスト | |
| CN116808038A (zh) | 阿片类物质和n-酰基乙醇胺的组合 | |
| JP5797655B2 (ja) | 消化管障害のためのオピオイド受容体アンタゴニストの使用 | |
| JP2013505260A5 (enExample) | ||
| US9849124B2 (en) | Systems and methods for treating an opioid-induced adverse pharmacodynamic response | |
| WO2007059445A2 (en) | Synergistic combinations of norketamine and opioid analgesics | |
| JP2005533046A5 (enExample) | ||
| ES2350439B1 (es) | Combinacion de un derivado del bencil-4,5-dihidro 1h-imidazol y un receptor opioide. | |
| CN114601819A (zh) | 一种水合氯醛在抑制阿片类药物复吸中的应用 | |
| JP2005529106A5 (enExample) | ||
| Vadivelu | Buprenorphine: and transdermal intravenous applications neuraxial | |
| JP2011513278A5 (enExample) |